{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:58:33Z","timestamp":1793746713334,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-01049-0","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:46:19Z","timestamp":1763829979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and validation of a UPLC-MS\/MS method for the quantification of asciminib and its pharmacokinetic interaction and metabolic stability with shikonin"],"prefix":"10.1186","volume":"26","author":[{"given":"Chenjian","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Que","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuegu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"1049_CR1","doi-asserted-by":"crossref","unstructured":"Koyama D, Kikuchi J, Kuroda Y, Ohta M, Furukawa Y. AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR\u2010ABL protein in CML cells. Cancer Sci. 2021.","DOI":"10.1111\/cas.14698"},{"key":"1049_CR2","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017.","DOI":"10.1056\/NEJMoa1609324"},{"key":"1049_CR3","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99:2191\u2013212.","journal-title":"Am J Hematol"},{"key":"1049_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","volume":"37","author":"MJ Mauro","year":"2023","unstructured":"Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior tkis: 4-year phase 1 safety and efficacy results. Leukemia. 2023;37:1048\u201359.","journal-title":"Leukemia"},{"key":"1049_CR5","doi-asserted-by":"publisher","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.","journal-title":"Leuk Res"},{"key":"1049_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"The allosteric inhibitor","year":"2017","unstructured":"The allosteric inhibitor. ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733\u20137.","journal-title":"Nature"},{"key":"1049_CR7","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Kim DW. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315\u201326.","journal-title":"N Engl J Med"},{"key":"1049_CR8","doi-asserted-by":"crossref","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.","DOI":"10.1016\/j.leukres.2020.106458"},{"key":"1049_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/CMAR.S353374","volume":"15","author":"N Hijiya","year":"2023","unstructured":"Hijiya N, Mauro MJ. Asciminib in the treatment of Philadelphia Chromosome-Positive chronic myeloid leukemia: focus on patient selection and outcomes. Cancer Manag Res. 2023;15:873\u201391.","journal-title":"Cancer Manag Res"},{"key":"1049_CR10","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"MJ Delphine.R\u00e9a, Mauro","year":"2021","unstructured":"Delphine.R\u00e9a, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031\u201341.","journal-title":"Blood"},{"key":"1049_CR11","doi-asserted-by":"crossref","unstructured":"Phi TranEggimann FK, JosephRay J. Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects. Xenobiotica: the fate of foreign compounds in biological systems. 2020;50.","DOI":"10.1080\/00498254.2019.1594449"},{"key":"1049_CR12","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1111\/cts.13285","volume":"15","author":"M Hoch","year":"2022","unstructured":"Hoch M, Huth F, Sato M, Sengupta T, Quinlan M, Dodd S, Kapoor S, Hourcade-Potelleret F. Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents. Clin Transl Sci. 2022;15:1698\u2013712.","journal-title":"Clin Transl Sci"},{"key":"1049_CR13","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/cts.13252","volume":"15","author":"M Hoch","year":"2022","unstructured":"Hoch M, Sengupta T, Hourcade-Potelleret F. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants. Clin Transl Sci. 2022;15:1406\u201316.","journal-title":"Clin Transl Sci"},{"key":"1049_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","volume":"82","author":"ED Deeks","year":"2022","unstructured":"Deeks ED. Asciminib: first approval. Drugs. 2022;82:219\u201326.","journal-title":"Drugs"},{"key":"1049_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2174\/1389200220666190325141422","volume":"20","author":"MK Parvez","year":"2019","unstructured":"Parvez MK, Rishi V. Herb-Drug interactions and hepatotoxicity. Curr Drug Metab. 2019;20:275\u201382.","journal-title":"Curr Drug Metab"},{"key":"1049_CR16","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/bmc.705","volume":"20","author":"AN Assimopoulou","year":"2010","unstructured":"Assimopoulou AN, Karapanagiotis I, Vasiliou A, Kokkini S, Papageorgiou VP. Analysis of Alkannin derivatives from Alkanna species by high-performance liquid chromatography\/photodiode array\/mass spectrometry. Biomed Chromatogr. 2010;20:1359\u201374.","journal-title":"Biomed Chromatogr"},{"key":"1049_CR17","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1016\/j.chroma.2009.01.098","volume":"1216","author":"A Albreht","year":"2009","unstructured":"Albreht A, Vovk I, Simonovska B, Srbinoska M. Identification of Shikonin and its ester derivatives from the roots of echium italicum L. J Chromatogr A. 2009;1216:3156\u201362.","journal-title":"J Chromatogr A"},{"key":"1049_CR18","doi-asserted-by":"crossref","unstructured":"Sankawa E. Miyazaki, Isomura, Otsuka: Antitumor activity of shikonin and its derivatives. Chemical & pharmaceutical bulletin 1977.","DOI":"10.1248\/cpb.25.2392"},{"key":"1049_CR19","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1142\/S0192415X20500780","volume":"48","author":"S Wang","year":"2020","unstructured":"Wang S, Long S, Deng Z, Wu W. Positive role of Chinese herbal medicine in cancer immune regulation. Am J Chin Med. 2020;48:1577\u201392.","journal-title":"Am J Chin Med"},{"key":"1049_CR20","doi-asserted-by":"crossref","unstructured":"Krejbich P, Birringer M. The Self-Administered use of complementary and alternative medicine (CAM) supplements and antioxidants in cancer therapy and the critical role of Nrf-2-A systematic review. Antioxid (Basel). 2022;11.","DOI":"10.3390\/antiox11112149"},{"key":"1049_CR21","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.pharmthera.2024.108728","volume":"264","author":"M Li","year":"2024","unstructured":"Li M, Wang Y, Chen Y, Dong L, Liu J, Dong Y, Yang Q, Cai W, Li Q, Peng B, et al. A comprehensive review on Pharmacokinetic mechanism of herb-herb\/drug interactions in Chinese herbal formula. Pharmacol Ther. 2024;264:108728.","journal-title":"Pharmacol Ther"},{"key":"1049_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.toxlet.2017.09.014","volume":"281","author":"S Tang","year":"2017","unstructured":"Tang S, Chen A, Zhou X, Zeng L, Liu M, Wang X. Assessment of the Inhibition risk of Shikonin on cytochrome P450 via cocktail Inhibition assay. Toxicol Lett. 2017;281:74\u201383.","journal-title":"Toxicol Lett"},{"key":"1049_CR23","doi-asserted-by":"crossref","unstructured":"Hema H, Panigrahi N. Quantification of asciminib by LC-MS\/MS method in human plasma: validation and stability studies. J Appl Pharm Sci. 2024.","DOI":"10.7324\/JAPS.2024.163326"},{"key":"1049_CR24","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.14233\/ajchem.2023.27925","volume":"35","author":"P Sandhya","year":"2023","unstructured":"Sandhya P, Nataraj K, Rajendran V. Bio-analytical method development and validation of asciminib and its application to Pharmacokinetic studies in rat plasma by using RP-HPLC. Asian J Chem. 2023;35:1651\u20138.","journal-title":"Asian J Chem"},{"key":"1049_CR25","doi-asserted-by":"crossref","unstructured":"Pallavi S, Sowjanya G. Quantification of asciminib and its impurities: a RP-UPLC study. Res J Pharm Technol. 2024;3430\u20136.","DOI":"10.52711\/0974-360X.2024.00537"},{"key":"1049_CR26","unstructured":"Yedlapalli G, Kumar YG. Drug development and validation of a sensitive Bio-analytical LCMS\/MS method for quantification of Asciminib-a chronic myeloid leukemia drug in human plasma. J Drug Alcohol Res. 2023;12."},{"key":"1049_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.18596\/jotcsa.1228364","volume":"10","author":"P Gaddey","year":"2023","unstructured":"Gaddey P. A novel method development and validation by Ultra-Performance liquid chromatography for assay of asciminib in dosage form. J Turkish Chem Soc Sect A: Chem. 2023;10:529\u201340.","journal-title":"J Turkish Chem Soc Sect A: Chem"},{"key":"1049_CR28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3109\/03639045.2014.886697","volume":"41","author":"Z Wang","year":"2015","unstructured":"Wang Z, Sun W, Huang CK, Wang L, Xia MM, Cui X, Hu GX, Wang ZS. Inhibitory effects of Curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes. Drug Dev Ind Pharm. 2015;41:613\u20136.","journal-title":"Drug Dev Ind Pharm"},{"key":"1049_CR29","unstructured":"Bioanalytical Method Validation Guidance for Industry. [https:\/\/www.fda.gov\/media\/70858\/download#:~:text=This%20guidance%20helps%20sponsors%20of%20investigational%20new%20drug,studies%20that%20require%20toxicokinetic%20or%20biomarker%20concentration%20data.]."},{"key":"1049_CR30","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391:885\u201398.","journal-title":"N Engl J Med"},{"key":"1049_CR31","doi-asserted-by":"publisher","first-page":"111265","DOI":"10.1016\/j.cbi.2024.111265","volume":"404","author":"J Chen","year":"2024","unstructured":"Chen J, Hong F, Xia H, Shen Y, Chen X, Wu H, Lin G, Zhan R. Investigation of Ponatinib metabolism and drug-drug interactions with lycopene and Shikonin in vitro and invivo. Chem Biol Interact. 2024;404:111265.","journal-title":"Chem Biol Interact"},{"key":"1049_CR32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/13880209.2020.1751661","volume":"58","author":"H Wang","year":"2020","unstructured":"Wang H, Dong L, Qu F, He H, Sun W, Man Y, Jiang H. Effects of glycyrrhizin on the pharmacokinetics of nobiletin in rats and its potential mechanism. Pharm Biol. 2020;58:352\u20136.","journal-title":"Pharm Biol"},{"key":"1049_CR33","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.4103\/0366-6999.162512","volume":"128","author":"Y Yan","year":"2015","unstructured":"Yan Y, Furumura M, Gouya T, Iwanaga A, Teye K, Numata S, Karashima T, Li XG, Hashimoto T. Shikonin promotes skin cell proliferation and inhibits nuclear Factor-\u03baB translocation via proteasome inhibition in vitro. Chin Med J (Engl). 2015;128:2228\u201333.","journal-title":"Chin Med J (Engl)"},{"key":"1049_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, et al. Combining the allosteric inhibitor asciminib with Ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36:431\u2013e443435.","journal-title":"Cancer Cell"},{"key":"1049_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13020-019-0231-3","volume":"14","author":"Z Wang","year":"2019","unstructured":"Wang Z, Yin J, Li M, Shen J, Xiao Z, Zhao Y, Huang C, Zhang H, Zhang Z, Cho CH, Wu X. Combination of Shikonin with Paclitaxel overcomes multidrug resistance in human ovarian carcinoma cells in a P-gp-independent manner through enhanced ROS generation. Chin Med. 2019;14:7.","journal-title":"Chin Med"},{"key":"1049_CR36","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3109\/13880209.2014.952836","volume":"53","author":"YD Jin","year":"2015","unstructured":"Jin YD, Ren Y, Wu MW, Chen P, Lu J. Effect of Shikonin on multidrug resistance in HepG2: the role of SIRT1. Pharm Biol. 2015;53:1016\u201321.","journal-title":"Pharm Biol"},{"key":"1049_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jep.2018.01.026","volume":"216","author":"CS Huang","year":"2018","unstructured":"Huang CS, Chen HW, Lin TY, Lin AH, Lii CK. Shikonin upregulates the expression of drug-metabolizing enzymes and drug transporters in primary rat hepatocytes. J Ethnopharmacol. 2018;216:18\u201325.","journal-title":"J Ethnopharmacol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-01049-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:36:48Z","timestamp":1767069408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-025-01049-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-01049-0","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were demonstrated to be ethically acceptable and were carried out according to the Guidelines of the Experimental Animal Care and Use of Laboratory Animals of The First Affiliated Hospital of Wenzhou Medical University. All animal procedures and experimental protocols were approved by the Laboratory Animal Ethics Committee of The First Affiliated Hospital of Wenzhou Medical University (Ethics approval number: WYYY-IACUC-AEC-2024-038).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"216"}}